Royalty Pharma
RPRX
RPRX
312 hedge funds and large institutions have $8.16B invested in Royalty Pharma in 2023 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 138 increasing their positions, 113 reducing their positions, and 46 closing their positions.
Holders
312
Holders Change
-12
Holders Change %
-3.7%
% of All Funds
4.98%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.1%
New
35
Increased
138
Reduced
113
Closed
46
Calls
$40.5M
Puts
$11.8M
Net Calls
+$28.7M
Net Calls Change
+$12.1M
Top Buyers
| 1 |
1
Adage Capital Partners
Boston,
Massachusetts
|
$267M |
| 2 |
2
Two Sigma Investments
New York
|
$59.9M |
| 3 |
3
Two Sigma Advisers
New York
|
$54.3M |
| 4 |
SCM
4
Suvretta Capital Management
New York
|
$111M |
| 5 |
GC
5
GMT Capital
Atlanta,
Georgia
|
$25.2M |
